Aquestive Therapeutics
AQST
4.62
+0.01
+0.22%
Aquestive Therapeutics
US · AQST
#3650 by market cap
Listed 2018
4.62
+0.01
+0.22%
Live - 5344 symbols - heartbeat 318s ago
· 2026-10-08 07:23
Pre-market
4.50
-2.60%
After-hours
4.62
0.00%
- Market cap
- 579.86M
- P/E (TTM)i
- -7.00
- P/Bi
- -10.24
- EPSi
- -0.78
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on AQST?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 58.26% +0.26pp
- Institutions
- 206 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund27.55%
Hedge Fund12.59%
Family Office/Trust7.85%
Public Company4.19%
Individual/Insider2.77%
VC/PE Fund2.74%
Private Company2.35%
Insurance Company0.79%
Government Pension Fund0.21%
Other38.96%
Top holders as of 2026-06-30
Bratton Capital Management, L.P.
7.82% · 9.81M sh
BlackRock
6.43% · 8.07M sh
RTW Investments, LP
5.92% · 7.43M sh
Vanguard Capital Management, LLC
4.17% · 5.24M sh
Federated Hermes, Inc.
2.48% · 3.11M sh
State Street Global Advisors
2.33% · 2.93M sh
Geode Capital Management, LLC
2.09% · 2.62M sh
Samsara BioCapital LLC
1.99% · 2.50M sh
Bank of America Corporation
1.33% · 1.67M sh
Sio Capital Management, LLC
1.18% · 1.49M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Barber | Chief Executive Officer | 0.52% |
| Stephen Wargacki | Senior VP of Research & Development | 0.27% |
| Peter Boyd | Senior Vice President of IT, HR & Communications | 0.23% |
| A. Toth | Chief Financial Officer | 0.23% |
| Carl Kraus | Chief Medical Officer | 0.23% |
| Melina Cioffi | Senior Vice President of Regulatory Affairs | 0.22% |
| Sherry Korczynski | Officer | 0.19% |
| Lori Braender | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 0.18% |
| Douglas Bratton | Former Independent Director | 0.17% |
| Cassie Jung | Officer | 0.17% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.82 |
| 2026-09-08 | Peter Boyd | Senior Vice President of IT, HR & Communications | Derivative Exercise and Retained | +2,293 | $0.96 |
| 2026-09-08 | Sherry Korczynski | Officer | Derivative Exercise and Sale | -8,750 | $2.65–5.22 |
| 2026-09-07 | Daniel Barber | Chief Executive Officer | Derivative Exercise and Retained | +91,743 | $0.96 |
| 2026-09-02 | Cassie Jung | Officer | Derivative Exercise and Retained | +4,587 | $0.96 |
| 2026-08-16 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.29 |
| 2026-08-13 | Sherry Korczynski | Officer | Sale to Issuer | -2,714 | $4.25 |
| 2026-07-15 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.00–4.03 |
| 2026-07-14 | Daniel Barber | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $4.04 |
| 2026-06-22 | Julie Krop | Independent Director | Derivative Exercise and Sale | -25,000 | $0.71–5.02 |
| 2026-06-14 | Daniel Barber | Chief Executive Officer | Open Market Disposition | -25,000 | $4.16 |
| 2026-06-09 | Timothy Morris | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Gregory Brown | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Julie Krop | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | John Cochran | Independent Vice Chairperson | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Marco Taglietti | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-09 | Abigail Jenkins | Independent Director | Other Derivative Acquisition | +50,500 | $3.99 |
| 2026-06-07 | Sherry Korczynski | Officer | Sale to Issuer | -2,714 | -- |
| 2026-05-17 | Thomas Zalewski | Chief Legal Officer & Chief Compliance Officer | Other Acquisition | +100,000 | -- |
| 2026-05-17 | Thomas Zalewski | Chief Legal Officer & Chief Compliance Officer | Other Derivative Acquisition | +75,000 | $4.14 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:23:59 · For reference only, not investment advice and not tailored to your situation.